Department of Anesthesiology, VA Boston Healthcare System, West Roxbury, MA; Department of Anesthesiology and Perioperative Medicine, Tufts University School of Medicine, Boston, MA.
Department of Anesthesiology and Perioperative Medicine, Tufts University School of Medicine, Boston, MA; Department of Anesthesiology, St. Elizabeth's Medical Center, Brighton, MA.
J Cardiothorac Vasc Anesth. 2022 Apr;36(4):1040-1046. doi: 10.1053/j.jvca.2021.07.006. Epub 2021 Jul 9.
Calcium and magnesium are concentration-dependent pro- and anticoagulant cofactors, and magnesium behaves similarly to calcium in the presence of citrate. The authors hypothesized that magnesium can cause clot formation (primary objective) when mixed with coagulation factor-containing blood products diluted with different crystalloids in a rapid- infuser reservoir. A secondary objective was the observation of any infuser alarms and stops in the event of clotting.
An experimental in vitro study with blood products, crystalloids, magnesium, and calcium in a rapid infuser with a reservoir using a closed-loop system.
Anesthesia research laboratory at an urban academic tertiary medical center PARTICIPANTS: Not applicable.
Exposure of fresh frozen plasma (FFP) and packed red blood cells alone (control) or in combination with either normal saline (NS), lactated Ringer's solution (LR), or Plasma-Lyte A (PL) to increasing concentrations of magnesium sulphate (MgSO) up to 1 g. After each incremental MgSO change, the authors applied a specific pump-flow sequence in a closed-loop system with a rapid-infuser reservoir, and if no clot was observed, the authors incrementally added calcium chloride (CaCl) up to 1 g.
Observation of macroscopic clot and time to event, as well as occurrence and type of any pump alarms or stops. LR experiments resulted in clot observation in the reservoir by a dedicated observer after MgSO 275 ± 206 mg (95% confidence interval [CI], 9-541). Adding MgSO 1 g in the NS, PL, or the control experiments did not result in clot observation. Only when CaCl 166.7 ± 51.64 mg (95% CI, 112.0-22.01) was added to the combination of blood products alone or mixed with NS and PL, clotting occurred. The mean FFP volume was 281 ± 48.6 mL (range, 204-340 mL) and was not different between groups (p = 0.44). Pump alarms and stops were inconsistent.
The addition of magnesium to a combination of LR with coagulation factor- containing blood products consistently resulted in a visible blood clot in the rapid-infuser reservoir in the authors' experimental setup. In addition to MgSO 1 g in the control, NS, and PL experiments, CaCl is needed before a clot can be observed.
钙和镁是浓度依赖性的促凝和抗凝辅助因子,并且在柠檬酸存在的情况下,镁的行为类似于钙。作者假设,当在快速输注器储液器中用不同晶体稀释含有凝血因子的血液制品混合时,镁会导致凝血(主要目标)。次要目标是观察凝血时输注器警报和停止的情况。
在具有储液器的快速输注器中使用闭环系统对血液制品、晶体、镁和钙进行的体外实验研究。
城市学术三级医疗中心的麻醉研究实验室
不适用。
单独暴露于新鲜冷冻血浆(FFP)和浓缩红细胞(对照)或与生理盐水(NS)、乳酸林格氏液(LR)或 Plasma-Lyte A(PL)组合,逐渐增加硫酸镁(MgSO)浓度至 1g。在每个递增的 MgSO 变化后,作者在快速输注器储液器的闭环系统中应用特定的泵流序列,如果没有观察到凝血,则逐渐添加氯化钙(CaCl)至 1g。
观察宏观凝血和时间事件,以及任何泵警报或停止的发生和类型。LR 实验导致在观察器观察到储液器中出现凝血后硫酸镁 275 ± 206mg(95%置信区间[CI],9-541)。在 NS、PL 或对照实验中添加 1g MgSO 不会导致凝血观察。只有当单独添加血液制品或与 NS 和 PL 混合时添加 166.7 ± 51.64mg(95%CI,112.0-22.01)的 CaCl 时,才会发生凝血。单独的 FFP 体积平均为 281 ± 48.6mL(范围,204-340mL),各组之间无差异(p=0.44)。泵警报和停止不一致。
在作者的实验设置中,向含有 LR 的凝血因子血液制品混合物中添加镁会导致快速输注器储液器中出现可见的血凝块。除了对照、NS 和 PL 实验中的 1g MgSO 外,还需要 CaCl 才能观察到凝血。